Holen Sie sich die Stockscreener-App
43.79
0.11%
0.05
Handel nachbörslich:
43.79
Schlusskurs vom Vortag:
$43.74
Offen:
$44.7
24-Stunden-Volumen:
2.53M
Relative Volume:
1.12
Marktkapitalisierung:
$8.24B
Einnahmen:
$550.17M
Nettoeinkommen (Verlust:
$201.35M
KGV:
43.79
EPS:
1
Netto-Cashflow:
$232.07M
1W Leistung:
+1.16%
1M Leistung:
-2.97%
6M Leistung:
-30.78%
1J Leistung:
-20.38%
1-Tages-Spanne:
$43.51
$45.17
1-Wochen-Bereich:
$43.41
$46.75
52-Wochen-Spanne:
$43.21
$85.21
Doximity Inc Stock (DOCS) Company Profile
Firmenname
Doximity Inc
Sektor
Branche
Telefon
(650) 549-4330
Adresse
500 THIRD STREET, SUITE 510, SAN FRANCISCO
Vergleichen Sie DOCS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DOCS
Doximity Inc
|
43.79 | 8.23B | 550.17M | 201.35M | 232.07M | 1.00 |
|
VEEV
Veeva Systems Inc
|
240.12 | 39.64B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
66.27 | 12.16B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
HQY
Healthequity Inc
|
94.15 | 8.42B | 1.15B | 96.70M | -161.99M | 1.09 |
|
BTSG
Brightspring Health Services Inc
|
37.53 | 7.05B | 11.99B | 24.18M | 234.31M | 0.2956 |
Doximity Inc Stock (DOCS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-11-21 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-11-13 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2025-10-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-10-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-10-01 | Herabstufung | Goldman | Neutral → Sell |
| 2025-07-09 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-06-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-02-07 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-02-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-12-20 | Eingeleitet | Stephens | Equal-Weight |
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-11-15 | Eingeleitet | Goldman | Neutral |
| 2024-11-14 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-11-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2024-11-08 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-11-08 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2024-10-15 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-08-09 | Hochstufung | Needham | Hold → Buy |
| 2024-07-18 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2024-04-25 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2024-01-02 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-08-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-08-09 | Herabstufung | Needham | Buy → Hold |
| 2023-08-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-06 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-10-31 | Eingeleitet | Wells Fargo | Overweight |
| 2022-10-24 | Eingeleitet | Evercore ISI | In-line |
| 2022-10-13 | Eingeleitet | BTIG Research | Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-08-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-28 | Eingeleitet | Berenberg | Buy |
| 2022-05-18 | Bestätigt | BofA Securities | Neutral |
| 2022-05-18 | Bestätigt | Goldman | Buy |
| 2022-05-18 | Bestätigt | Guggenheim | Buy |
| 2022-05-18 | Bestätigt | Jefferies | Buy |
| 2022-05-18 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Bestätigt | Needham | Buy |
| 2022-04-07 | Eingeleitet | Guggenheim | Buy |
| 2022-04-04 | Eingeleitet | BofA Securities | Neutral |
| 2022-02-11 | Eingeleitet | Goldman | Buy |
| 2021-12-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-12-02 | Eingeleitet | Jefferies | Buy |
| 2021-11-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-11-10 | Bestätigt | Canaccord Genuity | Buy |
| 2021-11-10 | Bestätigt | Goldman | Neutral |
| 2021-11-10 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Bestätigt | Needham | Buy |
| 2021-11-10 | Bestätigt | Piper Sandler | Overweight |
| 2021-08-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-19 | Eingeleitet | Goldman | Neutral |
| 2021-07-19 | Eingeleitet | JP Morgan | Overweight |
| 2021-07-19 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-07-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-07-19 | Eingeleitet | Raymond James | Outperform |
| 2021-07-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-07-19 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Doximity Inc Aktie (DOCS) Neueste Nachrichten
Ex-Doximity Exec Cops To $2.5M Insider Trading Scheme - Law360
Doximity: RBC touts growth moat while Goldman sees valuation reset - Investing.com
Doximity's Double-Digit Growth Rate is Sustainable, RBC Says - MarketScreener
Will Doximity’s (DOCS) AI Momentum and US$31 Million Settlement Shift Its Core Investment Narrative? - Yahoo Finance
Raymond James reiterates Strong Buy on Doximity stock amid AI competition - Investing.com
Can Doximity Inc. stock outperform in 2025 bull market2025 Growth vs Value & Capital Protection Trade Alerts - ulpravda.ru
How Doximity Inc. stock reacts to global recession fearsEarnings Trend Report & AI Enhanced Trading Signals - ulpravda.ru
Toast, GitLab, Doximity, Commvault, and Braze Stocks Trade Down, What You Need To Know - Finviz
Doximity stock initiated with Outperform rating by RBC Capital By Investing.com - Investing.com India
Doximity stock initiated with Outperform rating by RBC Capital - Investing.com India
Assessing Doximity (DOCS) Valuation After Volatile Trading And Recent AI Product Updates - Yahoo Finance
Is Doximity Inc. stock attractive for long term wealth building2025 Pullback Review & Reliable Trade Execution Plans - ulpravda.ru
Is Doximity Inc. stock attractive for ETFs2025 Sector Review & Free Risk Controlled Daily Trade Plans - ulpravda.ru
Will Doximity Inc. stock benefit from upcoming earnings reports2025 Buyback Activity & Risk Managed Trade Strategies - ulpravda.ru
Raymond James sees strong growth for Doximity stock amid stable pharma budgets By Investing.com - Investing.com India
Raymond James sees strong growth for Doximity stock amid stable pharma budgets - Investing.com UK
Will Doximity Inc. stock keep outperforming rivalsWeekly Risk Report & Risk Controlled Swing Trade Alerts - ulpravda.ru
Stop Loss: Why Doximity Inc. Class stock could be top winnerWatch List & Low Risk Entry Point Guides - ulpravda.ru
Truist Securities upgrades Doximity stock to Buy on market share gains By Investing.com - Investing.com Nigeria
Truist Securities upgrades Doximity stock to Buy on market share gains - Investing.com Nigeria
Truist Financial Upgrades Doximity (NASDAQ:DOCS) to "Buy" - MarketBeat
Hims & Hers Plunges 39.2% in 3 Months: Time to Hold the Stock or Sell? - TradingView — Track All Markets
Is Doximity Inc. Class stock among top earnings playsJuly 2025 Opening Moves & Free Real-Time Market Sentiment Alerts - ulpravda.ru
Doximity (DOCS) Ascends While Market Falls: Some Facts to Note - sharewise.com
Q3 Earnings Roundup: Doximity (NYSE:DOCS) And The Rest Of The Vertical Software Segment - Barchart.com
Doximity, Inc. (NASDAQ:DOCS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
MongoDB, Doximity, DoubleVerify, and 8x8 Shares Skyrocket, What You Need To Know - Finviz
Hims & Hers Expands Data-Driven, AI-Enabled Care and Personalization - TradingView — Track All Markets
Should You Investigate Doximity, Inc. (NYSE:DOCS) At US$43.29? - Yahoo Finance
Doximity, Inc. $DOCS Shares Acquired by Synergy Asset Management LLC - MarketBeat
EPS Watch: Will Doximity Inc stock keep outperforming rivalsPrice Action & Low Risk Growth Stock Ideas - moha.gov.vn
Doximity (NASDAQ:DOCS) Sets New 12-Month LowTime to Sell? - MarketBeat
Doximity stock hits 52-week low at 43.22 USD By Investing.com - Investing.com Nigeria
Doximity stock hits 52-week low at 43.22 USD - Investing.com
Fort Washington Investment Advisors Inc. OH Has $16.45 Million Position in Doximity, Inc. $DOCS - MarketBeat
Doximity reaches $31M settlement in securities litigation lawsuit - MSN
Doximity enters into $31 million settlement agreement to resolve securities litigation - MarketScreener
DoximityOn December 24, Enters Into $31 Million Settlement Agreement To Resolve Securities Litigation - TradingView — Track All Markets
Doximity Enters Agreement to Settle Securities Litigation for $31 Million - marketscreener.com
Doximity to settle securities litigation lawsuit for $31M - TipRanks
Doximity Reaches Proposed Settlement in Securities Litigation Case - TipRanks
Doximity reaches $31M settlement in securities litigation lawsuit (DOCS:NYSE) - Seeking Alpha
Doximity, Inc. Reaches Settlement in Securities Litigation - TradingView — Track All Markets
Doximity (NYSE: DOCS) agrees to $31M insured settlement in securities case - Stock Titan
Doximity Agrees to $31 Million Deal to End Investor Class Action - Bloomberg Law News
Doximity: Strong Growth but What's Next? - AOL.com
Here Are Monday’s Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More - AOL.com
Here are Monday’s top Wall Street analyst research calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and more - MSN
Why Doximity, Inc. (DOCS) Soared Last Week? - MSN
Raymond James reiterates Strong Buy on Doximity stock, cites physician-first approach By Investing.com - Investing.com Nigeria
Raymond James reiterates Strong Buy on Doximity stock, cites physician-first approach - Investing.com Nigeria
Finanzdaten der Doximity Inc-Aktie (DOCS)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.43%
4.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):